Henry Schein, Inc. (HSIC) Stock Analysis 2026

HealthcareMedical Distribution
$86.44
as of 2026-10-29
+28.4% (52-week)50D MA $86.75  |  200D MA $78.73

BriMind AI Score

Proprietary
40
Neutral
Price CAGR
3.8%
1Y Return
+33.1%
Analyst Upside
+15.6%
Rev Growth
6.7%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$94.29+9.1% potential
Bear Case
$63.90
Bull Case
$115.16
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($91.72) and Wall Street's consensus target ($96.87).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

HSIC Revenue & Profitability Breakdown

This chart shows how HSIC's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$13.60B
Cost of Revenue
-$9.34B
Gross Profit
$4.26B31.3% margin
Operating Expenses
-$3.48B
Operating Income
$782.8M5.8% margin
Tax & Other
-$379.8M
Net Income
$403.0M3.0% margin
Gross Margin
31.3%
Operating Margin
5.8%
Net Margin
3.0%

Key Financial Metrics

Henry Schein, Inc. trades at a trailing P/E of 26.10x, generates $446.0M in free cash flow, runs a debt/equity ratio of 80.73, and converts shareholder equity into profit at a 8.9% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$9.98B
P/E (Trailing)
26.10
P/E (Forward)
14.92
PEG Ratio
2.04
Revenue
$13.60B
Revenue Growth
6.7%
Earnings Growth
17.1%
Gross Margin
31.3%
Operating Margin
5.8%
Net Margin
3.0%
Return on Equity
8.9%
Return on Assets
4.4%
Free Cash Flow
$446.0M
Debt / Equity
80.73
Current Ratio
1.32
Quick Ratio
0.55
Beta
0.81
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
0.8%
Inst. Ownership
111.8%
Short % Float
7.5%
Book Value / Share
$28.21

Wall Street Analyst Consensus

Wall Street analysts covering Henry Schein, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $98.19 (+13.6% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$98.19+13.6% upside

Technical Price Signals

HSIC is currently in a short-term downtrend, trading below its 50-day average of $86.75 and above its 200-day average of $78.73. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$86.44
50-Day MA
$86.75
▼ Price below
200-Day MA
$78.73
▲ Price above
Short-term Downtrend
Below 50-day MA — caution

Further Reading

Research and guides that put HSIC’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

FundamentalsFactor Investing Guide 2026: Value, Momentum, Quality & Low Volatility — Which Factors Work?Risk ManagementHow to Build Your First Investment Portfolio: Risk Tolerance, Asset Allocation & Your First 5 FundsFundamentalsWarren Buffett Retired 2026: Berkshire Portfolio Under Greg AbelBeginnerWhat Is an AI Stock Score? How BriMindInvest Ranks Stocks

More Healthcare Stock Analysis

In-depth reports on companies operating alongside HSIC — business models, bull and bear cases, and the metrics that matter.

CAHCardinal Health, Inc.Medical DistributionMCKMcKesson CorporationMedical DistributionABBVAbbVie Inc.Drug Manufacturers - GeneralAMGNAmgen Inc.Drug Manufacturers - GeneralPRMEPrime Medicine, Inc.BiotechnologyTEMTempus AI, Inc.Health Information ServicesRXRXRecursion Pharmaceuticals, Inc.BiotechnologyEWEdwards Lifesciences CorporationMedical Devices

Unlock the Full HSIC Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis